**Background:** Pretransplant respiratory virus infection among patients undergoing HCT has been previously shown to have a negative impact on transplant outcomes in HCT recipients of all ages (Clin Inf Dis 61:192, 2015). We examined the impact of pretransplant detection of 11 respiratory viruses in a pediatric HCT population.

**Method:** Patients transplanted from 3/2010 to 3/2016 were retrospectively studied through day 100 post-HCT. All pediatric patients were universally screened for respiratory viruses prior to HCT using RT-PCR. Respiratory virus test results \<90 days before HCT were included. Viruses were categorized into three groups: adenoviruses, respiratory syncytial virus, influenza viruses, human metapneumovirus, and parainfluenza viruses type 1-4 (group 1); human rhinoviruses (group 2); and human coronaviruses (group 3). HCT was delayed whenever possible if any respiratory virus was detected pre-HCT. Transplant outcomes included "days alive and out of hospital by day 100" post-HCT (analyzed by univariable and multivariate linear regression models) and overall mortality (estimated and analyzed by Kaplan-Meir curves and Cox models).

**Results:** Of 218 pediatric HCT recipients, respiratory viruses were detected prior to HCT in 81 patients (37%). Group 2 viruses were most commonly detected (24%), followed by group 1 (11%) and group 3 (2%). Median day of last positive virus test result prior to transplant was −16 (IQR −27 to −11). Death occurred in 3% (6/218) of all patients by day 100 (only in allograft recipients). No significant difference in overall mortality was seen between children with and without pretransplant respiratory virus detection in all patients and in the allogeneic HCT subset.

In a multivariable linear regression analysis in allogeneic HCT recipients, patients with group 1 and group 2 viruses had significantly fewer days alive and out of hospital compared to those without a pretransplant virus (mean difference: group 1, −12.7, 95% CI −21.9 to −3.5, *P* = .007; group 2, −7.4, 95% CI −14.0 to −.9, *P* = .026; group 3, −9.6, 95% CI, −31.3 to 12.1, *P* = .386) after adjusting for recipients\' age \<5 years at transplant (mean difference vs. ≥5 years: −7.3, 95% CI, −13.6 to −1.1, *P*=.021) and cord blood as a stem cell source (mean difference vs. non-cord recipients: −12.0, 95% CI −18.6 to −5.4, *P* \< .001).

**Conclusion:** In pediatric HCT recipients, pretransplant detection of respiratory viruses, including human rhinoviruses, is associated with increased hospitalization within the first 100 days. More data are needed to define the reasons for prolonged hospitalization in children with pretransplant respiratory virus detection.
